Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
MMSI vs INVA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
MMSI vs INVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $3.72B | $1.93B |
| Revenue (TTM) | $1.54B | $424M |
| Net Income (TTM) | $139M | $504M |
| Gross Margin | 48.7% | 76.2% |
| Operating Margin | 12.2% | 14.8% |
| Forward P/E | 15.5x | 11.9x |
| Total Debt | $898M | $269M |
| Cash & Equiv. | $449M | $551M |
MMSI vs INVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
| Innoviva, Inc. (INVA) | 100 | 163.2 | +63.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MMSI vs INVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MMSI is the clearest fit if your priority is long-term compounding.
- 214.6% 10Y total return vs INVA's 94.9%
INVA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.13
- Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.5% revenue growth vs MMSI's 11.7% | |
| Value | Lower P/E (11.9x vs 15.5x) | |
| Quality / Margins | 118.9% margin vs MMSI's 9.0% | |
| Stability / Safety | Beta 0.13 vs MMSI's 0.71, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +21.7% vs MMSI's -33.8% | |
| Efficiency (ROA) | 32.4% ROA vs MMSI's 5.2%, ROIC 14.2% vs 7.2% |
MMSI vs INVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MMSI vs INVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MMSI is the larger business by revenue, generating $1.5B annually — 3.6x INVA's $424M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to MMSI's 9.0%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.5B | $424M |
| EBITDAEarnings before interest/tax | $290M | $86M |
| Net IncomeAfter-tax profit | $139M | $504M |
| Free Cash FlowCash after capex | $274M | $181M |
| Gross MarginGross profit ÷ Revenue | +48.7% | +76.2% |
| Operating MarginEBIT ÷ Revenue | +12.2% | +14.8% |
| Net MarginNet income ÷ Revenue | +9.0% | +118.9% |
| FCF MarginFCF ÷ Revenue | +17.8% | +42.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.8% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.8% | +4.0% |
Valuation Metrics
INVA leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 76% valuation discount to MMSI's 29.3x P/E. On an enterprise value basis, INVA's 8.1x EV/EBITDA is more attractive than MMSI's 13.1x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $3.7B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $4.2B | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | 29.26x | 6.91x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.46x | 11.91x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.67x |
| EV / EBITDAEnterprise value multiple | 13.06x | 8.10x |
| Price / SalesMarket cap ÷ Revenue | 2.45x | 4.55x |
| Price / BookPrice ÷ Book value/share | 2.38x | 1.65x |
| Price / FCFMarket cap ÷ FCF | 17.24x | 9.88x |
Profitability & Efficiency
INVA leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $9 for MMSI. INVA carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to MMSI's 0.57x. On the Piotroski fundamental quality scale (0–9), MMSI scores 6/9 vs INVA's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +8.9% | +46.5% |
| ROA (TTM)Return on assets | +5.2% | +32.4% |
| ROICReturn on invested capital | +7.2% | +14.2% |
| ROCEReturn on capital employed | +7.9% | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.57x | 0.23x |
| Net DebtTotal debt minus cash | $450M | -$282M |
| Cash & Equiv.Liquid assets | $449M | $551M |
| Total DebtShort + long-term debt | $898M | $269M |
| Interest CoverageEBIT ÷ Interest expense | 10.74x | 63.45x |
Total Returns (Dividends Reinvested)
INVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $9,644 for MMSI. Over the past 12 months, INVA leads with a +21.7% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors INVA at 25.0% vs MMSI's -9.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -27.9% | +14.7% |
| 1-Year ReturnPast 12 months | -33.8% | +21.7% |
| 3-Year ReturnCumulative with dividends | -26.5% | +95.2% |
| 5-Year ReturnCumulative with dividends | -3.6% | +94.4% |
| 10-Year ReturnCumulative with dividends | +214.6% | +94.9% |
| CAGR (3Y)Annualised 3-year return | -9.8% | +25.0% |
Risk & Volatility
INVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than MMSI's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.7% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.71x | 0.13x |
| 52-Week HighHighest price in past year | $100.19 | $25.15 |
| 52-Week LowLowest price in past year | $59.74 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +62.2% | +90.7% |
| RSI (14)Momentum oscillator 0–100 | 34.9 | 39.9 |
| Avg Volume (50D)Average daily shares traded | 769K | 621K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MMSI as "Buy" and INVA as "Buy". Consensus price targets imply 65.2% upside for INVA (target: $38) vs 52.4% for MMSI (target: $95).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $95.00 | $37.67 |
| # AnalystsCovering analysts | 13 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% |
INVA leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
MMSI vs INVA: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MMSI or INVA a better buy right now?
For growth investors, Innoviva, Inc.
(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus 11. 7% for Merit Medical Systems, Inc. (MMSI). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MMSI or INVA?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus Merit Medical Systems, Inc. at 29. 3x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x.
03Which is the better long-term investment — MMSI or INVA?
Over the past 5 years, Innoviva, Inc.
(INVA) delivered a total return of +94. 4%, compared to -3. 6% for Merit Medical Systems, Inc. (MMSI). Over 10 years, the gap is even starker: MMSI returned +214. 6% versus INVA's +94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MMSI or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus Merit Medical Systems, Inc. 's 0. 71β — meaning MMSI is approximately 464% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 57% for Merit Medical Systems, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MMSI or INVA?
By revenue growth (latest reported year), Innoviva, Inc.
(INVA) is pulling ahead at 18. 5% versus 11. 7% for Merit Medical Systems, Inc. (MMSI). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to 4. 9% for Merit Medical Systems, Inc.. Over a 3-year CAGR, MMSI leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MMSI or INVA?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus 8. 5% for Merit Medical Systems, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 12. 2% for MMSI. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MMSI or INVA more undervalued right now?
On forward earnings alone, Innoviva, Inc.
(INVA) trades at 11. 9x forward P/E versus 15. 5x for Merit Medical Systems, Inc. — 3. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.
08Which pays a better dividend — MMSI or INVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MMSI or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +94. 9%, MMSI: +214. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MMSI and INVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MMSI is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.